Physician profile
Robin Ashinoff
NPI 1811956600
$39,991.50
in general payments reported to CMS, 2019-2025
23 companies · $8,984 in 2025
The $8,984 reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.43 · 2020: $6,655 · 2021: $4,965 · 2022: $8,726 · 2023: $10K · 2024: $293 · 2025: $8,984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,644 · Consulting Fee: $7,500 · Food and Beverage: $1,300 · Travel and Lodging: $1,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,644.00 |
| Consulting Fee | $7,500.00 |
| Food and Beverage | $1,300.14 |
| Travel and Lodging | $1,130.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $18,716.10 | 2020-2025 | Libtayo, Dupixent |
| Genzyme Corporation | $10,373.32 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $8,939.16 | 2020-2025 | Blu-U, Odomzo, Absorica Ld |
| Almirall LLC | $468.98 | 2020-2024 | Klisyri |
| Amgen INC. | $269.23 | 2021-2024 | Otezla |
| Abbvie INC. | $201.90 | 2022-2025 | Rinvoq, Skyrizi |
| Eli Lilly and Company | $175.00 | 2022 | |
| Genentech USA, INC. | $151.32 | 2019-2022 | |
| Vector Surgical, LLC | $150.00 | 2022 | |
| Lilly USA, LLC | $141.11 | 2023-2024 | Taltz, Olumiant, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.16 | 2022-2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $64.00 | 2023-2024 | Zoryve |
| Merck Sharp & Dohme LLC | $41.94 | 2019-2023 | Keytruda |
| Leo Pharma INC. | $33.73 | 2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $28.72 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solta Medical, A Division of Bausch Health US, LLC | $23.11 | 2025 | |
| Ani Pharmaceuticals, INC. | $18.76 | 2025 | Oxistat |
| Organon LLC | $17.30 | 2025 | |
| Iovance Biotherapeutics, INC. | $17.26 | 2025 | Amtagvi |
| Ucb, INC. | $16.06 | 2024 | Bimzelx |
| Incyte Corporation | $15.19 | 2023 | Opzelura |
| Galderma Laboratories, L.P. | $13.70 | 2020 | |
| Epi Health, LLC | $13.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Ashinoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.